Polyelectrolyte microcapsules (PMCs) fabricated by layer-by-layer assembly require predictable shell stability for applications in drug delivery, biosensing, and environmental remediation. While core template type is known to influence stability, the role of polyelectrolyte layer number in governing poly(allylamine hydrochloride) (PAH) desorption remains poorly understood. This study quantitatively assessed PAH desorption from fluorescein isothiocyanate (FITC)-labeled shells of PMCs templated on CaCO3 or MnCO3 cores with 7, 9, or 13 layers under varying ionic conditions (distilled water, NaCl 0.2-3.0 M, Na2SO4 0.005-1 M) over 168 h. Short-term incubations revealed no significant layer-dependent desorption differences for either core type. However, prolonged exposure uncovered a non-monotonic relationship for CaCO3-templated PMCs: 7-layer capsules exhibited high initial but limited subsequent release (<50% increase), 9-layer capsules showed minimal initial dissociation followed by maximal kinetic amplification (up to 2000% increase), and 13-layer capsules displayed intermediate behavior. In contrast, MnCO3-templated PMCs demonstrated uniformly low initial dissociation with gradual time- and concentration-dependent release irrespective of layer number. These findings establish core template nature as the dominant factor controlling dissociation kinetics, while layer number enables fine-tuning of release profiles-particularly for CaCO3 systems-providing design principles for controlled-release applications requiring delayed or sustained payload delivery.

BACKGROUND:Clinical monitoring of metabolic disorders requires stable tools for simultaneous analyte detection. However, conventional free-enzyme assays suffer from rapid degradation, poor operational stability, and single-use limitations. Herein, we report a novel bi-enzymatic diagnostic system based on the rational co-encapsulation of glucose oxidase (GOx) and urease within polyelectrolyte microcapsules (PMCs) for the simultaneous determination of glucose and urea. RESULTS:Fabricated via layer-by-layer assembly, the PMCs achieved high enzyme loading (73 ± 2% for GOx and 93 ± 5% for urease). Co-encapsulation significantly reduced the GOx Michaelis constant from 10.1 to 2.5 mM. The system exhibited linear ranges of 0.5-3.0 mM (glucose) and 1-40 mM (urea), covering clinically relevant concentrations. It maintained performance for over 61 measurement cycles and a 27-day shelf-life at room temperature. Direct analysis of human saliva revealed that the PMCs effectively shield enzymes from matrix interferences, yielding significantly lower data dispersion and higher reproducibility than standard Clark-electrode and Berthelot reference methods. SIGNIFICANCE:By combining multi-cycle reusability, room-temperature stability, and enhanced precision in raw biological fluids, this co-encapsulation strategy overcomes the fundamental trade-offs of traditional immobilization. The developed PMCs provide a robust, cost-effective, and comprehensive platform for point-of-care metabolic diagnostics and non-invasive monitoring, establishing a generalizable framework for future multi-enzymatic biosensing applications.

Fluorescein-based tracers like uranine are extensively used in hydrogeology, textile marking, and cosmetics, yet their discharge generates dilute wastewater streams that challenge conventional treatment due to low removal efficiency and high operational costs. This study evaluates the sorption potential of polyelectrolyte microcapsules (PMCs) fabricated via a green, aqueous layer-by-layer (LbL) assembly on sacrificial CaCO3 templates for uranine decontamination. The PMCs achieve rapid equilibrium within ≤5 min, with kinetics governed by the pseudo-second-order model and equilibrium data described by the Langmuir isotherm, yielding a maximum capacity of 12.1 mg/g. Sorption is highly efficient at neutral to mildly acidic pH (3.0–7.0) and low ionic strength (≤0.15 M NaCl), providing 98–100% removal from dilute streams (C0 ≤ 10 mg/L) and consistently reducing effluent concentrations to <0.05 mg/L. Saturated capsules exhibit low spontaneous dye release (≤10%) in deionized water under the tested conditions. Although limited regenerability precludes multi-cycle industrial use, the rapid sorption kinetics and high uranine removal efficiency make PMCs well suited for single-use polishing applications. By offering a scalable, solvent-free synthesis and targeted removal of emerging fluorescent pollutants from low-concentration effluents, this work presents a sustainable, low-energy alternative for advanced wastewater treatment, aligning with green chemical engineering and circular water management principles.

The encapsulation of hydrophobic substances remains a significant challenge due to limitations such as low loading efficiency, leakage, and poor distribution within microcapsules. This study introduces a novel strategy utilizing colloidosomes assembled from polyelectrolyte microcapsules (PMCs). PMCs were fabricated via layer-by-layer (LbL) assembly on manganese carbonate (MnCO3) or calcium carbonate (CaCO3) cores, followed by core dissolution. A solvent gradient replacement method was employed to substitute the internal aqueous phase of PMCs with kerosene, enabling the formation of colloidosomes through self-assembly upon resuspension in water. Comparative analysis revealed that MnCO3-based PMCs with smaller diameters (2.5–3 µm vs. 4.5–5.5 µm for CaCO3) exhibited 3.5-fold greater stability, attributed to enhanced inter-capsule interactions via electrostatic and hydrophobic forces. Confocal microscopy confirmed the structural integrity of colloidosomes, featuring a liquid kerosene core encapsulated within a PMC shell. Temporal stability studies indicated structural degradation within 30 min, though 5% of colloidosomes retained integrity post-water evaporation. PMC-based colloidosomes exhibit significant application potential due to their integration of colloidosome functionality with PMC-derived structural features—semi-permeability, tunable shell thickness/composition, and stimuli-responsive behavior—enabling their adaptability to diverse technological and biomedical contexts. This innovation holds promise for applications in drug delivery, agrochemicals, and environmental technologies, where controlled release and stability are critical. The findings highlight the role of core material selection and solvent engineering in optimizing colloidosome performance, paving the way for advanced encapsulation systems.

Enzymatic analysis methods are widely used for the determination of low-molecular-weight substances in various fields; however, they have several limitations. One promising approach to addressing these limitations is the encapsulation of enzymes in polyelectrolyte microcapsules (PMCs). In this study, the development of a bienzymatic diagnostic system based on two separately encapsulated enzymes-urease and glucose oxidase (GO)-is proposed for the first time, enabling the simultaneous determination of urea and glucose concentrations in a single sample. To achieve this, the influence of reaction products and substrates of urease on the activity of GO, and vice versa, was investigated. It was demonstrated that ammonia reduces the activity of glucose oxidase, while gluconic acid and hydrogen peroxide decrease the activity of urease, with the PMC shell exhibiting protective properties for the encapsulated form of urease. Other reaction components did not affect the enzyme activities. The linear range, coefficient of variation, and reusability of this diagnostic system were determined: the linear range for urea concentration detection was found to be between 10 and 50 mM (coefficient of variation 2 %) with 7 reuses of same PMC-urease; the linear range for glucose concentration detection was between 30 and 100 mM (coefficient of variation 8 %) with 13 reuses of same PMC-GO. This diagnostic system is suitable for determining urea and glucose concentrations in industrial biofuel production and in industrial fermenters using urea as a nitrogen source.

Polyelectrolyte microcapsules (PMC) based on polyallylamine and polystyrene sulfonate are utilized in various fields of human activity, including medicine, textiles, and the food industry, among others. However, characteristics such as microcapsule size, shell thickness, and pore size are not sufficiently studied and systematized, even though they determine the possibility of using microcapsules in applied tasks. The aim of this review is to identify general patterns and gaps in the study of the morphology of polyelectrolyte microcapsules obtained by the alternate adsorption of polystyrene sulfonate and polyallylamine on different solid cores. First and foremost, it was found that the morphological change in polyelectrolyte microcapsules formed on different cores exhibits a significant difference in response to varying stimuli. Factors such as ionic strength, the acidity of the medium, and temperature have different effects on the size of the microcapsules, the thickness of their shells, and the number and size of their pores. At present, the morphology of the microcapsules formed on the melamine formaldehyde core has been most studied, while the morphology of microcapsules formed on other types of cores is scarcely studied. In addition, modern methods of nanoscale system analysis will allow for an objective assessment of PMC characteristics and provide a fresh perspective on the subject of research.

Allapinin has antiarrhythmic activity and can be used to prevent and treat various supraventricular and ventricular arrhythmias. Nevertheless, it is highly toxic and has a number of side effects associated with non-specific accumulation in various tissues. The complex of this substance with the monoammonium salt of glycyrrhizic acid (Al:MASGA) has less toxicity and improved antiarrhythmic activity. However, the encapsulation of Al:MASGA in polyelectrolyte microcapsules (PMC) for prolonged release will reduce the residual adverse effects of this drug. In this work, the possibility of encapsulating the allapinin–MASGA complex in polyelectrolyte microcapsules based on polyallylamine and polystyrene sulfonate was investigated. The encapsulation methods of the allapinin–MASGA in polyelectrolyte microcapsules by adsorption and coprecipitation were compared. It was found that the coprecipitation method did not result in the encapsulation of Al:MASGA. The sorption method facilitated the encapsulation of up to 80% of the original substance content in solution in PMC. The release of the encapsulated substance was further investigated, and it was shown that the release of the encapsulated Al:MASGA was independent of the substance content in the capsules, but at pH 5, a two-fold decrease in the rate of drug release was observed.

More than half of the global population is unable to consume dairy products due to lactose intolerance (hypolactasia). Current enzyme replacement therapy methods are insufficiently effective as a therapeutic approach to treating lactose intolerance. The encapsulation of β-galactosidase in polyelectrolyte microcapsules by using the layer-by-layer method could be a possible solution to this problem. In this study, adsorption and co-precipitation methods were employed for encapsulating β-galactosidase in polyelectrolyte microcapsules composed of (polyallylamine /polystyrene sulphonate)₃. As a result, the co-precipitation method was chosen for β-galactosidase encapsulation. The adsorption method permits to encapsulate six times less enzyme compared with the co-precipitation method; the β-galactosidase encapsulated via the co-precipitation method released no more than 20% of the initially encapsulated enzyme in pH 2 or 1 M NaCl solutions. In contrast, when using the sorption method, about 100% of the initially encapsulated enzyme was released from the microcapsules under the conditions described above. The co-precipitation method effectively prevents the complete loss of enzyme activity after 2 h of incubation in a solution with pH 2 while also alleviating the adverse effects of ionic strength. Consequently, the encapsulated form of β-galactosidase shows promise as a potential therapeutic agent for enzyme replacement therapy in the treatment of hypolactasia.

Phenols are widely used in industries despite their toxicity, which requires governments to limit their concentration in water to 5 mg/L before discharge to the city sewer. Thus, it is essential to develop a rapid, simple, and low-cost detection method for phenol. This study explored two pathways of peroxidase immobilization to develop a phenol detection system: peroxidase encapsulation into polyelectrolyte microcapsules and peroxidase captured by CaCO3. The encapsulation of peroxidase decreased enzyme activity by 96%; thus, this method cannot be used for detection systems. The capturing process of peroxidase by CaCO3 microspherulites did not affect the maximum reaction rate and the Michaelis constant of peroxidase. The native peroxidase—Vmax = 109 µM/min, Km = 994 µM; CaCO3–peroxidase—Vmax = 93.5 µM/min, Km = 956 µM. Ultimately, a reusable phenol detection system based on CaCO3 microparticles with immobilized peroxidase was developed, capable of detecting phenol in the range of 700 ng/mL to 14 µg/mL, with an error not exceeding 5%, and having a relatively low cost and production time. The efficiency of the system was confirmed by determining the content of phenol in a paintwork product.

Atrial fibrillation is one of the most common cardiac arrhythmias. Pharmacological preparations are used for treatment to control heart rate and rhythm. Amiodarone is one of these highly effective preparations, but, at the same time, it has significant toxicity and nonspecific accumulation in tissues. The drug delivery system based on polyelectrolyte microcapsules is one of the solutions. For this purpose, we compared different encapsulation methods of amiodaron: monoammonium salt of glycyrrhizic acid (Am:MASGA) complex (molar ratio 1:8). The concentration of amiodarone was determined by spectrophotometric methods at 251 nm. It has been shown that the co-precipitation method allows capturing 8% of Am:MASGA by CaCO3 microspherulites, which is not sufficient for the long-acting drug. The adsorption method allows encapsulating more than 30% of Am:MASGA into CaCO3 microspherulites and polyelectrolyte microcapsules CaCO3(PAH/PSS)(3), but, at the same time, an insignificant amount of substance is released into the incubation medium. The development of delivery and long-acting drug system based on such methods are not inexpedient. The most appropriate encapsulation method of Am:MASGA is the adsorption method into polyelectrolyte microcapsules with complex interpolyelectrolyte structure (PAH/PSS)(3). Such a type of PMC adsorbed about 50% of the initial amount of the substance and 25-30% of Am:MASGA was released into the medium after 115 h of incubation. The adsorption of Am:MASGA by polyelectrolyte microcapsules has electrostatic nature as evidenced by the acceleration of the release by 1.8 times as ionic strength increases

Anthropogenic activity negatively affects the environment by polluting it with the salts of various metals. One of the ways to reduce this influence is to use water purification methods for the salts of various metals. Water purification methods based on nanomaterials are promising. In this regard, we proposed to study polyelectrolyte microcapsules (PMC) as a promising sorption agent for the salts of various metals. It was found that the polystyrene sulfonate-polyallylamine (PSS-PAH) polyelectrolyte complex and polyelectrolyte microcapsules of different compositions are not able to adsorb salts CuSO4, Pb(NO)3, FeCl3, and CuCl2. At the same time, it was found that all types of capsules, except for (PSS/PAH)2/PSS, are capable of sorbing about 420 µg of K3[Fe(CN)6] and about 500 µg of K4[Fe(CN)6] from solution. The adsorption of polyelectrolyte microcapsules has an electrostatic nature which is confirmed by increases in the sorption capacity of PMC of K3[Fe(CN)6] and K4[Fe(CN)6] with decreases in the pH of the solution. Also, It was confirmed that the sorption process of PMC of K3[Fe(CN)6] and K4[Fe(CN)6] is concentration dependent and has the limitation of the number of binding sites.

Antimicrobial resistance is a global public health threat. One of the possible ways to solve this problem is phage therapy, but the instability of bacteriophages hinders the development of this approach. A bacteriophage delivery system that stabilizes the phage is one of the possible solutions to this problem. This study is dedicated to exploring methods to create encapsulated forms of bacteriophages for delivery. We studied the effect of proteolytic enzymes on the destruction of the polyelectrolyte microcapsule shell and revealed that protease from Streptomyces griseus was able to destroy the membrane of the microcapsule (dextran sulfate/polyarginine)3 ((DS/PArg)3). In addition, the protease decreased the activity of the bacteriophage in the second hour of incubation, and the phage lost activity after 16 h. It was found that a medium with pH 9.02 did not affect the survival of the bacteriophage or E. coli. The bacteriophages were encapsulated into polyelectrolyte microcapsules (DS/PArg)3. It was established that it is impossible to use microcapsules as a means of delivering bacteriophages since the bacteriophages are inactivated. When bacteriophages were included inside a CaCO3 core, it was demonstrated that the phage retained activity before and after the dissolution of the CaCO3 particle. From the results of this study, we recommend using CaCO3 microparticles as a container for bacteriophage delivery through the acidic stomach barrier.

Controlled release of substance from polyelectrolyte microcapsules is a triggered degradation of the microcapsule membrane that is extensive enough to release the contained substances out into the environment. Membrane degradation can be a result of enzymatic digestion, ultrasound or light exposure, heating, application of a magnetic field, pH or ionic strength changes in the solution or bacteria-mediated processes. This technology can be used for the targeted release of drugs, and for the development of self-healing materials and new generation pesticides.

Polyelectrolyte microcapsules (PMCs) are used in the development of new forms of drugs, coatings and diagnostic systems. Their buffer capacity, depending on the conditions of the medium, has not been practically studied, although it can affect the structure of both the capsule itself and the encapsulated agents. In this connection, we studied the buffer capacity of polyelectrolyte microcapsules of the composition (polystyrene sulfonate/polyallylamine)3 ((PSS/PAH)3) depending on the concentration and the type of salt in solution, as well as the microcapsule incubation temperature. It was found that the buffer capacity of microcapsules in the presence of mono- and di-valent salts of the same ionic strength did not differ practically. Increasing the NaCl concentration to 1 M led to an increase of buffer capacity of PMCs at pH ≥ 5, and an increase in NaCl concentration above 1 M did not change buffer capacity. The study of the buffer capacity of pre-heated PMCs showed that buffer capacity decreased with increasing incubation temperature, which was possibly due to the compaction of the PMCs and an increase in the number of compensated PAH sites. The addition of 1 M sodium chloride to heated PMCs presumably reversed the process described above, since an increase in the ionic strength of the solution led to an increase of the buffer capacity of the PMCs. The effects described above confirm the hypothesis put forward that the buffer properties of microcapsules are determined by uncompensated PAH regions in their composition.

Polyelectrolyte microcapsules can be applied as microcontainers for the delivery of a wide range of substances, and it is important to search for new methods for capsule destruction and releasing substances from them. In this work, we studied the possibility of using sodium dodecyl sulfonate (SDS) for the release of fluorescein isothiocyanate—dextran from six-layer microcapsules composed of PAH and PSS. It was shown that the presence of SDS in the medium, at a concentration of 3000 μg/ml, leads to the destruction of polyelectrolyte microcapsules and the release of the substance from them (54% of the amount of the encapsulated substance), while the main part of the FITC-dextran released during the first hours of incubation. At an SDS concentration of 100 μg/ml, the substance released is uniform and is 44% in 24 h. At SDS concentrations from 50 to 100 μg/ml, the process of destruction of microcapsules proceeds more slowly. At SDS concentrations from 10 to 50 μg/ml, microcapsules are not degraded.

Sodium dodecyl sulfate (SDS) is the most widely used anionic surfactant. Its frequent use causes environmental pollution and negative effects on living organisms (even at low concentrations ≈ 20 μg/ml). Thus, cheap and fast methods are needed to detect this surfactant in wastewater and surface waters in order to prevent the negative effects of SDS on the environment and human beings. We discovered that sodium dodecyl sulfate is capable of destroying polyelectrolyte microcapsules, which has been demonstrated by the number of sedimented polyelectrolyte microcapsules (PMC) before and after incubation in SDS solution. Therefore, it was proposed to use PMCs to create qualitative and quantitative diagnostic systems for the determination of SDS in solution. The qualitative system is a polyelectrolyte microcapsules containing polyallylamine labeled with a fluorescent dye-FITC. An excess SDS concentration of more than 5 μg/ml in the analyzed medium leads to the destruction of PMC and an increase in the fluorescence intensity of the solution, which is recorded by a fluorometer. The quantitative diagnostic system is based on turbidimetry of the PMC suspension before and after incubation in an anionic surfactant solution. This system has a range of detectable SDS concentrations from 10 to 50 μg/ml, with a standard deviation of no more than 11%.

Polyelectrolyte microcapsules are used in the development of new forms of targeted delivery systems, self-healing materials, sensors, and smart materials. Nevertheless, their buffer capacity has not been practically studied, although that characteristic makes it possible to estimate the change in the state of protonation of the entire polyelectrolyte system. This is necessary both for creating a buffer barrier system for pH-sensitive compounds (metals, enzymes, polyelectrolytes, drugs) and for the correct interpretation of the results of research and studying of the PMC structure. The buffer capacity of a PMC can be affected by the concentration of microcapsules in solution and the number of shell layers since the listed parameters affect other physicochemical properties of the PMC shell. This includes, for example, the electrical conductivity, permeability (of ions), osmotic pressure, charge density, etc. In this regard, we studied the change in the buffer capacity of polyelectrolyte microcapsules depending on their concentration and the number of shell layers. As a result, it was found that with an increasing concentration of microcapsules, the buffering capacity of the PMC increases, but at the same time, in the pH range from 4 to 5.5, the calculated buffering capacity of 1 billion capsules decreases with increasing their concentration. This effect may be associated with a decrease in the available -NH2 groups of the PMC's shell. In addition, it was found that the main contribution to the buffer capacity of a PMC is made by the entire shell of the microcapsule and not just its surface. At the same time, the buffer capacity of the capsules has non-linear growth with an increase in the number of PMC shell layers. It is presumably associated either with a decrease in the polyelectrolyte layer with an increase in their number or with a decrease in the permeability of hydrogen protons.

Polyelectrolyte microcapsules, which are obtained by the method of alternate adsorption of oppositely charged polyelectrolytes onto colloidal particles of micron size, are widely used in science and industry. Nevertheless, the properties of microcapsules are still poorly understood. In particular, there is no information in the literature on the buffer capacity. However, information on the presence of a buffer capacity and an understanding of its mechanisms can both simplify the use of microcapsules and expand the scope of their application. In this regard, the buffer capacity of various types of microcapsules was studied. It was found that polyelectrolyte microcapsules consisting of polyallylamine, and polystyrene sulfonate have a buffer capacity. In addition, in an acidic medium, the buffer capacity of microcapsules containing BSA is significantly greater than that of microcapsules without protein. This is due to the fact that BSA contributes to the buffering of microcapsules. Differences in the behaviour of the buffer capacity of microcapsules with the composition (PAH/PSS)3 and (PSS/PAH)3 were found. In addition, a hypothesis has been proposed that regions of unbound polyallylamine are responsible for the buffering properties of polyelectrolyte microcapsules. This hypothesis is confirmed by the fact that incubation of microcapsules in 0.5 M NaCl increases the amount of unbound polyallylamine, which leads to an increase in the buffer capacity of microcapsules at alkaline pH values higher than the buffer capacity of capsules in an aqueous solution.

Phage therapy is a great alternative to antibiotic drugs, but it can’t effectively overcome the over-acidic medium of the stomach. We offer the use of polyelectrolyte microcapsules as a protective means of bacteriophage. It is necessary to understand the influence of polyelectrolytes on bacteriophage survival. The work studied the effect of polyanions and polycations on the coliprotetic bacteriophage’s viability. We have shown that polyallylamine decreased bacteriophage’s viability during increasing polyelectrolyte concentration and polyarginine had a lower inhibitory effect (then PAH) on the activity of the bacteriophage due to polyelectrolyte concentration from 0.05 to 5 mg/mL. It was shown that the inhibition of the bacteriophage by polyallylamine had an electrostatic nature and the use of high ionic strength prevented the formation of the PAH-protein capsid complex. Polystyrene sulfonate does not affect bacteriophage viability during increasing polyelectrolyte concentration from 0.05 mg/mL to 1 mg/mL. Polystyrene sulfonate decreases the viability of bacteriophage from 5 mg/mL of polyelectrolyte concentration. Dextran sulfate inhibits bacteriophage activity at 20–30%. Dextran inhibits bacteriophage activity by 80% at diapason concentration from 0.05 to 5 mg/mL and loses the inhibition effect from a concentration of 5 mg/mL.